32
Participants
Start Date
June 15, 2013
Primary Completion Date
September 21, 2018
Study Completion Date
September 21, 2018
Dacomitinib
PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Collaborators (1)
Pfizer
INDUSTRY
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER